WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 414319
CAS#: 138-39-6 (free base)
Description: Mafenide Free Base is a sulfonamide that inhibits the enzyme CARBONIC ANHYDRASE and is used as a topical anti-bacterial agent, especially in burn therapy.
MedKoo Cat#: 414319
Name: Mafenide Free Base
CAS#: 138-39-6 (free base)
Chemical Formula: C7H10N2O2S
Exact Mass: 186.0463
Molecular Weight: 186.229
Elemental Analysis: C, 45.15; H, 5.41; N, 15.04; O, 17.18; S, 17.22
Related CAS #: 138-39-6 (free base) 12001-72-8 (propionate) 138-37-4 (HCl) 138-39-6 (acetate)
Synonym: Mafenide Free Base; NSC34632; NSC-34632; NSC 34632
IUPAC/Chemical Name: 4-(aminomethyl)benzenesulfonamide
InChi Key: TYMRLRRVMHJFTF-UHFFFAOYSA-N
InChi Code: InChI=1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11)
SMILES Code: NCc1ccc(S(=O)(N)=O)cc1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | Mafenide is an effective sulfonamide-type antimicrobial agent used for burn wounds. Mafenide shows activity against both Gram-positive and Gram-negative organisms, including Pseudomonas aeruginosa, via inhibition of nucleotide synthesis. |
| In vitro activity: | MAF (mafenide) could inhibit pyroptosis in iBMDM and microglia BV2, and decrease the release of inflammatory factors. MAF could inhibit GSDMD cleavage by directly binding to the GSDMD-Asp275 site, while the expression of p30-GSDMD was simultaneously down-regulated and the release of inflammatory factors was decreased. Reference: Eur J Pharm Sci. 2020 Apr 30;147:105303. https://pubmed.ncbi.nlm.nih.gov/32173407/ |
| In vivo activity: | MAF (mafenide) could reduce the levels of inflammatory factors in cerebrospinal fluid and peripheral blood of APP/PS1 mice, and suppress the activation of microglia. Reference: Eur J Pharm Sci. 2020 Apr 30;147:105303. https://pubmed.ncbi.nlm.nih.gov/32173407/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMF | 30.0 | 161.09 | |
| DMSO | 30.0 | 161.09 | |
| DMSO:PBS (pH 7.2) (1:4) | 0.2 | 1.07 |
The following data is based on the product molecular weight 186.229 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Han C, Yang Y, Yu A, Guo L, Guan Q, Shen H, Jiao Q. Investigation on the mechanism of mafenide in inhibiting pyroptosis and the release of inflammatory factors. Eur J Pharm Sci. 2020 Apr 30;147:105303. doi: 10.1016/j.ejps.2020.105303. Epub 2020 Mar 12. Erratum in: Eur J Pharm Sci. 2022 Mar 1;170:106099. PMID: 32173407. |
| In vitro protocol: | 1. Han C, Yang Y, Yu A, Guo L, Guan Q, Shen H, Jiao Q. Investigation on the mechanism of mafenide in inhibiting pyroptosis and the release of inflammatory factors. Eur J Pharm Sci. 2020 Apr 30;147:105303. doi: 10.1016/j.ejps.2020.105303. Epub 2020 Mar 12. Erratum in: Eur J Pharm Sci. 2022 Mar 1;170:106099. PMID: 32173407. |
| In vivo protocol: | 1. Han C, Yang Y, Yu A, Guo L, Guan Q, Shen H, Jiao Q. Investigation on the mechanism of mafenide in inhibiting pyroptosis and the release of inflammatory factors. Eur J Pharm Sci. 2020 Apr 30;147:105303. doi: 10.1016/j.ejps.2020.105303. Epub 2020 Mar 12. Erratum in: Eur J Pharm Sci. 2022 Mar 1;170:106099. PMID: 32173407. |
1: Rizzo JA, Martini AK, Pruskowski KA, Rowan MP, Niece KL, Akers KS. Thermal stability of mafenide and amphotericin B topical solution. Burns. 2018 Mar;44(2):475-480. doi: 10.1016/j.burns.2017.08.019. Epub 2017 Sep 19. PMID: 28935221.
2: Afshari A, Nguyen L, Kahn SA, Montgomery AC, Shinha T, Stratton C, Summitt B. The Effective Duration of Antimicrobial Activity of Mafenide Acetate After Reconstitution. J Burn Care Res. 2018 Aug 17;39(5):736-738. doi: 10.1093/jbcr/irx029. PMID: 29931082.
3: Afshari A, Nguyen L, Kahn SA, Summitt B. 2.5% Mafenide Acetate: A Cost- Effective Alternative to the 5% Solution for Burn Wounds. J Burn Care Res. 2017 Jan/Feb;38(1):e42-e47. doi: 10.1097/BCR.0000000000000425. PMID: 27606553.
4: Bandmann HJ, Breit R. The mafenide story. Br J Dermatol. 1973 Aug;89(2):219-21. PMID: 4269480.
5: Kahn SA, Afshari A, Nguyen L, Shinha T, Huff T, Montgomery AC, Stratton C, Summitt B. Hydrofiber Dressing Saturated With Mafenide Acetate Extends the Duration of Antimicrobial Activity. J Burn Care Res. 2017 Jul/Aug;38(4):e704-e707. doi: 10.1097/BCR.0000000000000455. PMID: 27775984.
6: Mendelson JA. Topical mafenide hydrochloride aqueous spray in initial management of massive contaminated wounds with devitalized tissue. Prehosp Disaster Med. 2001 Jul-Sep;16(3):172-4. doi: 10.1017/s1049023x00025930. PMID: 11875802.
7: Punjataewakupt A, Napavichayanun S, Aramwit P. The downside of antimicrobial agents for wound healing. Eur J Clin Microbiol Infect Dis. 2019 Jan;38(1):39-54. doi: 10.1007/s10096-018-3393-5. Epub 2018 Oct 5. PMID: 30291466.
8: Mafenide acetate cream: a review. Drugs. 1971;1(6):434-60. doi: 10.2165/00003495-197101060-00002. PMID: 4948236.
9: Firoz EF, Firoz BF, Williams JF, Henning JS. Allergic contact dermatitis to mafenide acetate: a case series and review of the literature. J Drugs Dermatol. 2007 Aug;6(8):825-8. PMID: 17763614.
10: Han C, Yang Y, Yu A, Guo L, Guan Q, Shen H, Jiao Q. Investigation on the mechanism of mafenide in inhibiting pyroptosis and the release of inflammatory factors. Eur J Pharm Sci. 2020 Apr 30;147:105303. doi: 10.1016/j.ejps.2020.105303. Epub 2020 Mar 12. PMID: 32173407.
